Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.66 |
| ▸ | KDR | P35968 | 3/20 | 0.66 |
| ▸ | ABL1 | P00519 | 2/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.66 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | BCR | P11274 | 1/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.66 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.66 |
| ▸ | ABL2 | P42684 | 1/20 | 0.66 |
| ▸ | FRK | P42685 | 1/20 | 0.66 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.66 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.66 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4249258 | 0.99 | MET (0.66) | METKDRABL1NTRK1EPHB6 | |
| Hydrochloric Acid SCHEMBL1727169 | 0.99 | MET (0.66) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL2250774 | 0.98 | MET (0.63) | METKDRABL1NTRK1EPHB6 | |
| Sulfuric Acid SCHEMBL4245717 | 0.97 | MET (0.63) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL2250789 | 0.95 | KDR (0.61) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL2255401 | 0.94 | MET (0.57) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL2252242 | 0.94 | MET (0.57) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL3559555 | 0.94 | MET (0.66) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL2251525 | 0.93 | MET (0.55) | METKDRABL1NTRK1EPHB6 | |
| SCHEMBL2252244 | 0.93 | KDR (0.56) | METKDRABL1NTRK1EPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586443-B1 | ANTITUMOR AGENT USING COMPOUNDS HAVING KINASE INHIBITORY EFFECT IN COMBINATION | EISAI R&D MAN CO LTD (JP) | 2016-03-16 | — | — | EP | claimed |
| US-9012458-B2 | Antitumor agent using compounds having kinase inhibitory effect in combination | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-21 | — | — | US | claimed |
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130123274-A1 | Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | claimed |
| EP-2586443-A1 | ANTITUMOR AGENT USING COMPOUNDS HAVING KINASE INHIBITORY EFFECT IN COMBINATION | Eisai R&D Management Co., Ltd. (JP) | 2013-05-01 | — | — | EP | claimed |
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | claimed |
| US-8377938-B2 | Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-19 | — | — | US | claimed |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2009142896-A3 | LANDSCAPE EDGING SYSTEM | WINK JOHN (US) | 2012-05-10 | — | — | WO | claimed |
| EP-2062886-B1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-30 | — | — | EP | claimed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | claimed |
| EP-2119706-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | Eisai R&D Management Co., Ltd. (JP) | 2009-11-18 | — | — | EP | claimed |
| US-20090227556-A1 | RECEPTOR TYROSINE KINASE INHIBITORS COMPRISING PYRIDINE AND PYRIMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | claimed |
| US-20090176797-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-09 | — | — | US | claimed |
| EP-2062886-A1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | claimed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | claimed |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-12-25 | — | — | US | claimed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | claimed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | claimed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227556-A1 | RECEPTOR TYROSINE KINASE INHIBITORS COMPRISING PYRIDINE AND PYRIMIDINE DERIVATIVES | RET, FLT1, KDR | MET 42/4885KDR 3/4885ABL1 19/4885 |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | HGF, MET, FLT1 | MET 2/4885KDR 9/4885ABL1 381/4885 |
| US-20090176797-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-10, H1-0 | MET 1876/4885KDR 4307/4885ABL1 3148/4885 |
| US-20130123274-A1 | Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination | MAP3K8, MAP3K20, MAP3K7 | MET 685/4885KDR 531/4885ABL1 27/4885 |
| US-20120232049-A1 | PYRIDINE OR PYRIMIDINE DERIVATIVE HAVING EXCELLENT CELL GROWTH INHIBITION EFFECT AND EXCELLENT ANTI-TUMOR EFFECT ON CELL STRAIN HAVING AMPLIFICATION OF HGFR GENE | HGF, MET, MKI67 | MET 2/4885KDR 119/4885ABL1 538/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MET 2/4885KDR 8/4885ABL1 886/4885 |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | FIP1L1, SKP1, TET2 | MET 1938/4885KDR 1759/4885ABL1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.